Aviso: Este site agrega dados públicos oficiais da FDA, ClinicalTrials.gov, PubMed e SEC EDGAR apenas para referência geral. Não constitui aconselhamento médico, diagnóstico, recomendação de tratamento ou aconselhamento de investimento.

PubMed

Characteristics of pivotal clinical trials of FDA-approved endovascular devices between 2000 and 2018: An interrupted time series analysis.

PMID: 37008598 ·

J, o, h, n, , T, , M, o, o, n, ;, , M, e, n, e, l, a, o, s, , K, o, n, s, t, a, n, t, i, n, i, d, i, s, ;, , N, e, v, o, n, , S, o, n, g, ;, , N, a, r, i, m, a, n, , N, e, z, a, m, i, ;, , B, i, l, l, , S, , M, a, j, d, a, l, a, n, y, ;, , A, l, l, e, n, , H, e, r, r, ;, , G, a, r, y, , S, i, s, k, i, n

RevistaJournal of clinical and translational science
Ano
PMID37008598

Resumo

The Food and Drug Administration (FDA) reviews safety, efficacy, and the quality of medical devices through its regulatory process. The FDA Safety and Innovation Act (FDASIA) of 2012 was aimed at accelerating the regulatory process for medical devices. The purpose of our study was to (1) quantify characteristics of pivotal clinical trials (PCTs) supporting the premarket approval of endovascular medical devices and (2) analyze trends over the last two decades in light of the FDASIA. We surveyed t

Fonte oficial

Ver no PubMed →

Dados provenientes do PubMed / NCBI. Para consultar o texto integral e as informações mais recentes, recorra sempre ao registo oficial.

↑